EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: exploring decision rules for clinical utility by Conaghan, P. et al.
EXTENDED REPORT
EULAR report on the use of ultrasonography in
painful knee osteoarthritis. Part 2: Exploring decision
rules for clinical utility
P Conaghan, M A D’Agostino, P Ravaud, G Baron, M Le Bars, W Grassi, E Martin-
Mola, R Wakefield, J-L Brasseur, A So, M Backhaus, M Malaise, G Burmester,
N Schmidely, P Emery, M Dougados
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations










Accepted 23 April 2005
Published Online First
5 May 2005
. . . . . . . . . . . . . . . . . . . . . . .
Ann Rheum Dis 2005;64:1710–1714. doi: 10.1136/ard.2005.038026
Background: Synovial inflammation (as defined by hypertrophy and effusion) is common in osteoarthritis
(OA) and may be important in both pain and structural progression.
Objective: To determine if decision rules can be devised from clinical findings and ultrasonography (US) to
allow recognition of synovial inflammation in patients with painful knee OA.
Methods: A EULAR-ESCISIT cross sectional, multicentre study enrolled subjects with painful OA knee who
had clinical, radiographic, and US evaluations. A classification and regression tree (CART) analysis was
performed to find combinations of predictor variables that would provide high sensitivity and specificity for
clinically detecting synovitis and effusion in individual subjects. A range of definitions for the two key US
variables, synovitis and effusion (using different combinations of synovial thickness, depth, and
appearance), were also included in exploratory analyses.
Results: 600 patients with knee OA were included in the analysis. For both knee synovitis and joint
effusion, the sensitivity and specificity were poor, yielding unsatisfactory likelihood ratios (75% sensitivity,
45% specificity, and positive LR of 1.36 for knee synovitis; 71.6% sensitivity, 43.2% specificity, and positive
LR of 1.26 for joint effusion). The exploratory analyses did not improve the sensitivity and specificity
(demonstrating positive LRs of between 1.26 and 1.57).
Conclusion: Although it is possible to determine clinical and radiological predictors of OA inflammation in
populations, CART analysis could not be used to devise useful clinical decision rules for an individual
subject. Thus sensitive imaging techniques such as US remain the most useful tool for demonstrating
synovial inflammation of the knee at the individual level.
O
steoarthritis (OA) of the knee is an increasingly
common problem placing huge burden on individual
subjects and health services, with the size of the
problem growing rapidly as the community grows older.1–4
The OA process is known to involve the whole joint.3
Synovitis is present from the earliest stages of OA and has
been reported to be progressively increased with increasing
severity of chondropathy.5 6 Recently, synovitis detected by
magnetic resonance imaging (MRI) has been associated with
joint pain in OA.7 Arthroscopically detected synovitis has also
been associated with progression of chondropathy.8 9 The
ability to detect synovitis may therefore be clinically useful
for a better understanding of pathogenesis and, possibly, for
predicting treatment response. In addition, early detection of
synovitis may allow specific targeting of treatments.
Although MRI may be the ‘‘gold standard’’ for determining
the presence of synovial inflammation, it is still relatively
expensive and optimal synovitis detection may require the
use of intravenous contrast agents. Recently, increasing
interest has been shown in ultrasonography (US)10 11 as it
provides a reliable, non-invasive tool that can be used in a
clinic setting for detecting both synovial hypertrophy and
effusions in small and large joints.12 13 At the knee, US has
been demonstrated to be more sensitive than clinical
examination in detecting synovitis13 14 and compares well
with MRI in the detection of effusion and Baker’s cyst.15
We conducted a large cross sectional study using US to
determine the presence of synovial inflammation in painful
knee OA.16 This project aimed at determining if clinical
decision rules could be developed that would provide high
levels of both sensitivity and specificity for detecting US
synovial inflammation (synovial hypertrophy or effusion) for
individual patients.
METHODS
This was a cross sectional, multicentre, prospective European
study conducted under the umbrella of the European League
Against Rheumatism (EULAR) Standing Committee for
International Clinical Studies Including Therapeutics Trials
(ESCISIT), enrolling subjects from seven European countries
(Belgium, France, Germany, Italy, Spain, Switzerland, and
the United Kingdom) who were recruited by 50 rheumatol-
ogists. Appropriate ethics committee permission was
obtained in each country and written informed consent was
obtained from every patient before study participation.
The main inclusion criteria were age>18, primary knee OA
according to the American College of Rheumatology defini-
tion,17 with radiographic Kellgren and Lawrence (K&L) grade
1–4,18 19 symptoms of at least 6 months’ duration, functional
capacity 1–3 according to the Steinbrocker functional score,20
and pain intensity at study entry >30 mm on a 100 mm
visual analogue scale that asked about pain in the previous
48 hours related to physical activities. Exclusion criteria
included any known cause for secondary OA, surgery on the
Abbreviations: CART, classification and regression tree; K&L, Kellgren
and Lawrence; LR, likelihood ratio; MRI, magnetic resonance imaging;
OA, osteoarthritis; US, ultrasonography
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study joint within the previous 12 months, intra-articular
corticosteroid injection within the previous 4 weeks, or intra-
articular radionuclide injection within the previous
3 months.
After informed consent was obtained, patients were
examined by a rheumatologist (investigator 1, 50 investiga-
tors in total), who collected all clinical and examination
findings. A radiologist or second rheumatologist experienced
in musculoskeletal US (investigator 2; 29 investigators in
total) then performed US of the study knee according to
prespecified US parameters. Table 1 summarises the clinical
and US evaluations recorded and the US technique is
described in detail in the first report from this study.16 The
following US definitions were employed as the primary
outcome:
N Synovitis—defined as hypoechoic synovium with thickness
>4 mm and diffuse or nodular appearance
N Joint effusion—maximal depth of the suprapatella recesses
measured on the median sagittal plane crossing the
quadriceps tendon (in mm); this was transformed into a
two point categorical scale where ‘‘absent’’ represented an
effusion depth ,4 mm and ‘‘present’’ represented an
effusion depth >4 mm.
The results of the clinical examination findings were not
shared with the ultrasonographer, but the ultrasonographer
was able to communicate in writing the results of the US
examination to investigator 1 as the treating clinician. Data
were recorded by the investigators on two separate case
report forms, which were forwarded to a central data entry
and quality control service.
Statistical analysis
The previous report on the US findings of the present cohort16
included a multivariate logistic regression model that
demonstrated the variables associated with the highest
probability of having US detected synovial inflammation,
according to the primary outcome definitions. However, such
probabilities are not generally useful for clinicians when
faced with an individual patient. To determine a systematic
way of predicting the presence or absence of US detected
abnormalities in a given patient, a classification and
regression tree (CART) analysis was performed, using CART
software (Salford System, San Diego, CA). These decision tree
models are technically known as binary recursive partition-
ing.21 22 A parent node is always split into two child nodes
(binary), the process is repeated for each child node
(recursive) and each split results in partitioning into
mutually exclusive subsets. The models aim to recursively
partition input variables in order to maximise the purity in a
terminal node. The decision to make a partitioning split is
done after searching each possible threshold for each variable
included in order to find the split that leads to the greatest
improvement in the purity score of the resultant node, and
cut off points are sought for continuous variables (rather
than deciding on an arbitrary dichotomous point). Each node
is split on just one variable.
A 10-fold cross validation was used for estimating
misclassification rates. The 10-fold cross validation split the
total sample into 10 subsamples. Trees were then generated
excluding the data from each subsample in turn. For each
tree, each misclassification rate was estimated by applying
the tree to the subsample excluded in generating the tree. The
cross validated rate estimate for the overall tree was
calculated as the average of the rates of the 10 trees. A
positive likelihood ratio (LR+ = sensitivity/12specificity)
was calculated for each decision tree, with an LR+ >3
considered desirable.
Because the definitions used for synovitis and effusions
were necessarily conservative, a number of other definitions
were explored to determine if useful clinical decision rules
could be established. These other definitions allowed for
combinations of variation in the size of what was considered
‘‘pathological’’ synovial hypertrophy or effusion depth and
used various combinations of synovial appearance. A CART
analysis was performed for the range of definitions, and
when clinical parameters were selected, they were included
in a subsequent logistic regression model. This model
proceeded with stepwise selection until no variables met
the criteria for entry (p,0.05) or removal (p.0.05) for the
significance levels of the likelihood ratio test.
RESULTS
Of 643 subjects enrolled in the study, 16 subjects (2.5%) had
only one case report form available from clinical or US
evaluation, so that there were 627 potentially analysable
subjects. Among these subjects, 27 (4.3%) had a major
protocol deviation, leaving a final analysis population of 600
Table 1 Summary of clinical and ultrasound evaluations
of the studied osteoarthritic knee
Clinical examination
Localisation (studied knee)
Date of knee OA* onset
Radiological grade (Kellgren & Lawrence score)
Clinical parameters (past 48 hours)
Patient’s global assessment of knee pain
Patient’s global assessment of clinical knee OA severity
Physician’s global assessment of clinical knee OA severity
WOMAC pain subscale
WOMAC stiffness subscale
WOMAC physical function subscale
Duration of morning stiffness
Night awakening due to knee pain
Knee joint effusion on clinical examination
Sudden aggravation of knee pain in previous 2 weeks
Previous and concomitant drug treatment for knee OA
Ultrasound examination
Knee synovitis
Measurement of synovial width
Appearance of synovial tissue
Joint effusion
Maximal width of subquadricipital recesses
Knee OA, knee osteoarthritis. WOMAC, Western Ontario and










% of synovitis = 24.2%
Pain > 91.5
(n = 36)
% of synovitis = 5.6%
% of synovitis = 9.8%
Figure 1 Decision tree for knee synovitis. K&L, Kellgren and Lawrence.
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subjects. The demographics, clinical, and US evaluations have
already been presented in detail.16 Briefly, the 600 included
subjects had a mean (SD) age of 66.7 (9.8), 165 (27.5%) were
male, and the mean (SD) body mass index was 29.9 (5.3).
When primary outcome definitions were used 322 (53.7%)
had no US evidence of inflammation, 16 (2.7%) had synovitis
alone, 177 (29.5%) had effusion alone, and 85 (14.2%) had
both synovitis and effusion.
CART analysis using primary outcome definitions
Figure 1 presents the decision tree for knee synovitis. When
this tree was used a sensitivity of 75% and a specificity of 45%
were obtained (see table 2), giving an LR+ of 1.36. Figure 2
presents the decision tree for knee effusion. When this tree
was used a sensitivity of 71.6% and a specificity of 43.2%
were obtained (see table 3), giving an LR+ of 1.26. Neither of
these results was considered satisfactory for clinical use.
CART analysis using exploratory definitions
Table 4 presents the CART results for three of the exploratory
definitions, together with the associated logistic regression
analyses. It is noteworthy that whatever the definition used,
subjects with knee OA with a more severe radiological grade
(K&L scores >3) and moderate or important knee joint
effusion on clinical examination had an increased likelihood
of synovitis or effusion being detected on US examination.
Unfortunately the CART selected LRs were again disappoint-
ing.
DISCUSSION
This study attempted to produce decision rules for the clinical
detection of synovial inflammation in patients with OA using
data derived from a large, multicentre European study of 600
knees. Unfortunately, at the individual subject level, the
CART analysis (using both primary definitions and variations
of these) did not produce an LR+ above 2. This means that
the selected variables would not be helpful clinically for
identifying synovial inflammation in a given patient. This
was despite the fact that the first report from this study
correlated clinical and ultrasonographic features at the group
level16 and showed that inflammation observed at US
correlated statistically with advanced radiographic disease
(K&L grades 3–4) and, at an earlier stage (K&L grades 1–2)
with clinical signs or symptoms suggestive of an inflamma-
tory flare of the disease (for example, sudden increase in pain
in the previous 2 weeks or clinical joint effusion).
The CART methodology employed here has been used
previously to define useful clinical algorithms in other
medical areas such as oncology23 and cardiology.24 In
rheumatology, Wolfe et al have demonstrated that clinical
features such as fatigue and sleep disturbance may be
usefully included in clinical CART algorithms using tradi-
tional measures (pain and tender joint counts) for predicting
change of treatment in the clinic.25 As they noted, there is
often an incongruity between clinical trials and routine
clinical practice in the feasibility of time consuming trial
evaluations. Similarly, we aimed at producing a useful tool
that did not require US for assessing people in the clinic,
rather than trying to extrapolate from findings at the group
level.
There are limitations to this study. Firstly, the imaging
method employed for the detection of inflammation was US.
Although gadolinium-enhanced MRI may (arguably) be
more sensitive in detecting synovitis, it would not have been
feasible to use it for such a large, multicentre cohort. The
definitions used for US detected disease were also conserva-
tive and based on the limited available published reports;
however, it is interesting that in the exploratory analyses,
even more encompassing definitions of synovial disease (for
example, synovial thickness >2 mm) did not yield a better
LR+ on CART analysis. The CART analysis itself has
limitations, although these do not seem to be greater than
other discrimination techniques used in clinical decision
making.24 Caution should be used in assuming that the
clinical features selected in the CART analyses are the most
important, but in this case the features (for example, severe
radiographic grade or very high levels of pain; figs 1 and 2)
selected would support the face validity of these analyses.
In summary, it would be desirable clinically to determine
accurate ‘‘subsets’’ of patients with OA in order to better
understand disease pathogenesis and clarify therapeutic
response; indeed our aim should be to tailor treatment to
the individual patient. We sought to determine easily
employed algorithms for detecting synovitis by the clinician.
However, the results of this study suggest that the most
Table 2 Classification table with sensitivity and
specificity obtained by 10-fold cross validation, used to
test the decision tree for knee synovitis shown in fig 1
Actual class
Predicted class
Actual totalNo synovitis Synovitis
No synovitis 225 275 500
Synovitis 25 75 100
Predicted total 250 350 600











% of effusion = 51.1%
CICI = no
(n = 176)
% of effusion = 25%
% of effusion = 51.4%
Figure 2 Decision tree for joint effusion. Note that data were missing
on one subject; hence 599 patients were included in this analysis. K&L,
Kellgren and Lawrence.
Table 3 Classification table with sensitivity and
specificity obtained by 10-fold cross validation, used to
test the decision tree for joint effusion shown in fig 2
Actual class
Predicted class
Actual totalNo effusion Effusion
No effusion 146 192 338
Effusion 74 187 261
Predicted total 220 379 599
Sensitivity = 71.6%, specificity = 43.2%; LR+ 1.26.
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sensitive and specific way of determining synovial hyper-
trophy and effusion is to use imaging, most feasibly US.
Longitudinal evaluation of this EULAR cohort will provide
information on the predictive validity of US detected synovial
pathology for OA disease progression.
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